Post-marketing surveillance study of valsartan/amlodipine combination in Taiwanese hypertensive patients

References

• Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010.
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206–1252.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: 1903–1913.
   PubMed Web of Science ®Google Scholar
• Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371: 1513–1518.
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang TD, Li YH, Lin TH, Chien KL, Yeh HI, . 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109:740–773.
   PubMed Web of Science ®Google Scholar
• Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, . Evidence for improved control of hypertension in Taiwan: 1993–2002. J Hypertens. 2008;26:600–606.
   PubMed Web of Science ®Google Scholar
• Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res. 2008;8:133.
   PubMed Web of Science ®Google Scholar
• Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL, Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10:185–194.
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61–73.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, . Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393–404.
   PubMedGoogle Scholar
• Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29:1065–1070.
   PubMed Web of Science ®Google Scholar
• Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, . A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, . Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, . Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. JHypertens. 2009;27:2121–2158.
   PubMed Web of Science ®Google Scholar
• Liou YS, Ma T, Tien L, Chien C, Chou P, Jong GP. Long-term effects of antihypertensive drugs on the risk of new-onset diabetes in elderly Taiwanese hypertensives. Int Heart J. 2008;49:205–211.
   PubMed Web of Science ®Google Scholar
• Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806.
   PubMed Web of Science ®Google Scholar
• Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007;99:1006–1012.
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2006;28:88–136.
   Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
   PubMed Web of Science ®Google Scholar
• Krzesinski JM, Cohen EP. Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. Core Evid. 2010;4:1–11.
   PubMedGoogle Scholar
• Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine. Adv Ther. 2008;25:300–320.
   PubMed Web of Science ®Google Scholar
• Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther. 2008;25:399–411.
   PubMed Web of Science ®Google Scholar
• Ke Y, Zhu D, Hong H, Zhu J, Wang R, Cardenas P, Zhang Y. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin. 2010;26:1705–1713.
   PubMed Web of Science ®Google Scholar
• Oparil S, Giles T, Ofili EO, Pitt B, Seifu Y, Hilkert R, . Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens. 2011;29: 161–170.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr. 2009;48:401–405.
   PubMed Web of Science ®Google Scholar
• Chazova IE, Dongre N, Vigdorchik AV. Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Adv Ther. 2011;28: 134–149.
   PubMed Web of Science ®Google Scholar
• Flack JM, Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. Expert Opin Pharmacother. 2009;10:1979–1994.
   PubMed Web of Science ®Google Scholar
• Ofili EOOparil S, Giles T, Pitt B, Purkayastha D, Hilkert R, . Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. J Am Soc Hypertens. 2011.
   Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–828.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317: 703–713.
   PubMed Web of Science ®Google Scholar
• Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med. 2010;362:1628–1630.
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419.
   PubMed Web of Science ®Google Scholar
• Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, . Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18.
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923–928.
   PubMed Web of Science ®Google Scholar
• Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23:479–489.
   PubMed Web of Science ®Google Scholar
• Schrader J, Salvetti A, Calvo C, Akpinar E, Keeling L, Weisskopf M, Brunel P. The combination of amlodipine/ valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009;63:217–225.
   PubMed Web of Science ®Google Scholar
• Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69:2393–2414.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, Ruilope LM. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35:1038–1042.
   PubMed Web of Science ®Google Scholar
• Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL. Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. Hypertension. 2006;48: 271–277.
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, . Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563–580.
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9: 355–364.
   PubMedGoogle Scholar
• Boutouyrie P, Achouba A, Trunet P, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55: 1314–1322.
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Preti P, Zoppi A, Derosa G. Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. Vasc Health Risk Manag. 2010;6:87–93.
   PubMedGoogle Scholar
• Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, . Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279–289.
   PubMed Web of Science ®Google Scholar
• Sinkiewicz W, Glazer RD, Kavoliuniene A, Miglinas M, Prak H, Wernsing M, Yen J. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin. 2009;25:315–324.
   PubMed Web of Science ®Google Scholar
• Braun N, Ulmer H-J, Ansari A, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10mg plus valsartan 160mg in hypertensive patients not controlled by amlodipine 10mg plus olmesartan 20mg in free combination. Current Medical Research and Opinion. 2009;25:421–430.
   PubMed Web of Science ®Google Scholar
• Trenkwalder P, Schaetzl R, Borbas E, Handrock R, Klebs S. Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. Blood Press. 2008;17 Suppl 2:13–21.
   Web of Science ®Google Scholar
• Schunkert H, Glazer RD, Wernsing M, Yen J, Macarie CE, Vintila MM, Romanova J. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr Med Res Opin. 2009;25:2655–2662.
   PubMed Web of Science ®Google Scholar
• Weber M. Clinical safety and tolerability of losartan. Clin Ther. 1997;19:604–616; discussion 603.
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Yagi S, Ebihara A, Doi Y, Domae A, Shibata A, . Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J. 1997;38: 831–840.
   PubMedGoogle Scholar
• Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128–135.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, . Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220–224.
   PubMed Web of Science ®Google Scholar